- One of the most-watched Alzheimer's therapies in the clinic,Biogen Inc(NASDAQ:BIIB)-Eisai Limited's(OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's.
- In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023.
- Also Read:This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval.
- Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's...
Login or create a forever free account to read this news
Sign up/Log in